Trial | NCT00345657  Report issue

Title

Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care
Extended-Release Niacin/Lovastatin Versus Usual Care for Treatment of Dyslipidemia in a Primary Care Setting (EXTEND Study)

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    niacin lovastatin ...

  • Study Participants

    100
The purpose of this study is to investigate the benefits of combination niacin ER/lovastatin in patients receiving standard care who are not at LDL goal per ATP III guidelines.
Both LDL and HDL are important contributors in the pathophysiology of atherosclerosis and coronary artery disease (CAD); however, HDL is often ignored in primary care. The combination of niacin extended-release (ER)/lovastatin in a single tablet formulation (Advicor®) may be the most effective therapeutic option for simultaneously correcting both of these lipoprotein abnormalities to reduce CAD risk. The purpose of this study is to investigate the benefits of combination niacin ER/lovastatin in patients receiving standard care who are not at LDL goal per ATP III guidelines.
Study Started
Jul 31
2003
Study Completion
May 31
2004
Last Update
Jun 28
2006
Estimate

Drug Niacin Extended Release/Lovastatin

Criteria 

Inclusion Criteria:

>18 years old with CAD or risk factors for CAD
under standard care at Family Medical Care of Tulsa
not at LDL goal per ATP III guidelines

Exclusion Criteria:

pregnancy/lactating
liver disease
allergies to statin or niacin
active peptic ulcer disease
previous treatment with combination therapy for dyslipidemia
No Results Posted